Integrative analysis revealed that distinct cuprotosis patterns reshaped tumor microenvironment and responses to immunotherapy of colorectal cancer
暂无分享,去创建一个
Xiao Yang | X. Yang | Sen Zhang | Hao Zhong | Ximo Xu | Duohuo Shu | Mengqin Yu | B. Feng | Chengsheng Ding | Sen Zhang | Ximo Xu | Chengsheng Ding | Hao Zhong | Wei Qin | Duohuo Shu | Mengqin Yu | Naijipu Abuduaini | Bo Feng | W. Qin | Naijipu Abuduaini
[1] Liying Song,et al. Comprehensive analyses of PDHA1 that serves as a predictive biomarker for immunotherapy response in cancer , 2022, Frontiers in Pharmacology.
[2] T. Golub,et al. Copper induces cell death by targeting lipoylated TCA cycle proteins , 2022, Science.
[3] Xiaojie Xie,et al. CXCR4-dependent macrophage-to-fibroblast signaling contributes to cardiac diastolic dysfunction in heart failure with preserved ejection fraction , 2022, International journal of biological sciences.
[4] M. Kriegsmann,et al. Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. , 2021, Cancer cell.
[5] G. Long,et al. Immune checkpoint inhibitors in melanoma , 2021, The Lancet.
[6] Qianhui Xu,et al. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer , 2021, Frontiers in Immunology.
[7] G. Mayhew,et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience , 2021, British Journal of Cancer.
[8] J. Joyce,et al. Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.
[9] Jianxun Song,et al. Metabolic Reprogramming and Reactive Oxygen Species in T Cell Immunity , 2021, Frontiers in Immunology.
[10] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[11] C. Kundu,et al. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[12] Yan Li,et al. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology , 2020, Briefings Bioinform..
[13] P. Gibbs,et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. , 2020, The New England journal of medicine.
[14] A. Zorzano,et al. Macrophage mitochondrial MFN2 (mitofusin 2) links immune stress and immune response through reactive oxygen species (ROS) production , 2020, Autophagy.
[15] D. Ettinger,et al. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. , 2020, JAMA oncology.
[16] H. Nader,et al. Effects of syndecan-4 gene silencing by micro RNA interference in anoikis resistant endothelial cells: Syndecan-4 silencing and anoikis resistance. , 2020, The international journal of biochemistry & cell biology.
[17] Young-Joon Kim,et al. Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer , 2020, Experimental & Molecular Medicine.
[18] Jasjit K. Banwait,et al. Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer. , 2020, Carcinogenesis.
[19] F. Ginhoux,et al. The Extended Polydimensional Immunome Characterization (EPIC) web-based reference and discovery tool for cytometry data , 2020, Nature Biotechnology.
[20] M. Mittelbrunn,et al. Glycolysis – a key player in the inflammatory response , 2020, The FEBS journal.
[21] M. Zheng,et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST , 2020, Molecular Cancer.
[22] Y. Saeys,et al. NicheNet: modeling intercellular communication by linking ligands to target genes , 2019, Nature Methods.
[23] T. Buchler,et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. , 2019, Pharmacology & therapeutics.
[24] Kongming Wu,et al. Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor , 2019, OncoTargets and therapy.
[25] De-Hua Wu,et al. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer , 2019, Clinical Cancer Research.
[26] H. Nader,et al. Heparan sulfate proteoglycans as trastuzumab targets in anoikis‐resistant endothelial cells , 2019, Journal of cellular biochemistry.
[27] Qiang Wu,et al. Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades , 2019, Front. Immunol..
[28] F. Song,et al. The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma , 2019, Oncoimmunology.
[29] J. Galon,et al. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.
[30] A. Butte,et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.
[31] Jacob D. Jaffe,et al. Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.
[32] C. Borner,et al. Copper-induced cell death and the protective role of glutathione: the implication of impaired protein folding rather than oxidative stress. , 2018, Metallomics : integrated biometal science.
[33] Yassen Assenov,et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.
[34] E. Alici,et al. The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment , 2018, Front. Immunol..
[35] S. Ricard-Blum,et al. Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics. , 2018, Chemical reviews.
[36] T. Ma,et al. miR‑21‑5p targets PDHA1 to regulate glycolysis and cancer progression in gastric cancer. , 2018, Oncology reports.
[37] X. Liu,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[38] Gang Yang,et al. Tumor microenvironment participates in metastasis of pancreatic cancer , 2018, Molecular Cancer.
[39] Shangha Pan,et al. PGC1α promotes cholangiocarcinoma metastasis by upregulating PDHA1 and MPC1 expression to reverse the Warburg effect , 2018, Cell Death & Disease.
[40] R. Weinberg,et al. Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.
[41] Ye Xu,et al. A robust gene signature for the prediction of early relapse in stage I–III colon cancer , 2018, Molecular oncology.
[42] Camille Stephan-Otto Attolini,et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.
[43] R. Bourgon,et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.
[44] A. Wree,et al. NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL‐17 and TNF in mice , 2018, Hepatology.
[45] E. Yates,et al. Coupling of vinculin to F-actin demands Syndecan-4 proteoglycan. , 2017, Matrix biology : journal of the International Society for Matrix Biology.
[46] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[47] Laurence Zitvogel,et al. The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.
[48] Tithi Ghosh,et al. Tumor promoting role of anti-tumor macrophages in tumor microenvironment. , 2017, Cellular immunology.
[49] Yumin Xia,et al. TWEAK/Fn14 signaling in tumors , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[50] Matthew L. Albert,et al. Dying cells actively regulate adaptive immune responses , 2017, Nature Reviews Immunology.
[51] A. Butte,et al. xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.
[52] I. Mellman,et al. Elements of cancer immunity and the cancer–immune set point , 2017, Nature.
[53] Pornpimol Charoentong,et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.
[54] Carlos Caldas,et al. Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study , 2016, PLoS medicine.
[55] P. Laurent-Puig,et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.
[56] J. Rathmell,et al. A guide to immunometabolism for immunologists , 2016, Nature Reviews Immunology.
[57] A. Chiu,et al. Role of Mitochondrial DNA Copy Number Alteration in Human Renal Cell Carcinoma † , 2016, International journal of molecular sciences.
[58] N. Gogtay,et al. Biostatistics Series Module 3: Comparing Groups: Numerical Variables , 2016, Indian journal of dermatology.
[59] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[60] L. Zitvogel,et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[61] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.
[62] Gianluca Bontempi,et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.
[63] Joshua A. Bittker,et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action , 2015, Nature chemical biology.
[64] J. Nesland,et al. Decreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma. , 2016, American journal of cancer research.
[65] S. Turley,et al. Immunological hallmarks of stromal cells in the tumour microenvironment , 2015, Nature Reviews Immunology.
[66] N. Savaskan,et al. Glioblastoma cells induce differential glutamatergic gene expressions in human tumor-associated microglia/macrophages and monocyte-derived macrophages , 2015, Cancer biology & therapy.
[67] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[68] N. Itano,et al. Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment , 2014, Cancers.
[69] G. Cline,et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.
[70] E. Tartour,et al. Control of the Immune Response by Pro-Angiogenic Factors , 2014, Front. Oncol..
[71] J. V. Van Ginderachter,et al. Mechanisms Driving Macrophage Diversity and Specialization in Distinct Tumor Microenvironments and Parallelisms with Other Tissues , 2014, Front. Immunol..
[72] D. Quail,et al. Microenvironmental regulation of tumor progression and metastasis , 2014 .
[73] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[74] T. Crocenzi,et al. Circulating and intratumoral macrophages in patients with hepatocellular carcinoma: correlation with therapeutic approach. , 2013, American journal of surgery.
[75] C. Gialeli,et al. Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab , 2013, Investigational New Drugs.
[76] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[77] R. Labianca,et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[78] Douglas Hanahan,et al. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .
[79] Witold R. Rudnicki,et al. Feature Selection with the Boruta Package , 2010 .
[80] Matthew D. Wilkerson,et al. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..
[81] V. Georgoulias,et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[82] B. Vértessy,et al. Keeping uracil out of DNA: physiological role, structure and catalytic mechanism of dUTPases. , 2009, Accounts of chemical research.
[83] M. J. van de Vijver,et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.
[84] D. Sargent,et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.